The last news released was 24 April and that was from Bio Prospect regarding Arabian Horse trials.
News from SLA was last issued on 22 April in the form of a Ropren update. The report was very positive and they said nine hospitals were waiting for their initial delivey and pricing would be released in May.
Now more that three months have passed and we have heard nothing.
For how long can the silence continue. Surely shareholders deserve more from their directors.
Von.
SLA Price at posting:
0.0¢ Sentiment: None Disclosure: Held